Pinnacle Associates Ltd. Has $9.12 Million Stake in Pfizer Inc. $PFE

Posted by Brenda Bartman on Aug 18th, 2026

Pinnacle Associates Ltd. lowered its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 8.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 378,796 shares of the biopharmaceutical company’s stock after selling 34,337 shares during the period. Pinnacle Associates Ltd.’s holdings in Pfizer were worth $9,121,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of PFE. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Keb Asset Management LLC acquired a new position in Pfizer during the second quarter valued at approximately $26,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Evolution Wealth Management Inc. increased its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Abound Financial LLC acquired a new stake in Pfizer in the fourth quarter worth $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.88 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market cap of $153.21 billion, a price-to-earnings ratio of 35.37 and a beta of 0.34. The stock’s 50-day moving average is $25.15 and its 200-day moving average is $26.20. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the company earned $0.78 earnings per share. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

Analyst Ratings Changes

PFE has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. JPMorgan Chase & Co. reduced their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Pfizer in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.28.

Read Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.